A health-tech startup building a low-cost, non-invasive diagnostic tool to detect biomarkers linked to stroke and Alzheimer’s disease risk through saliva. The platform also incubates next-gen medical researchers, enabling innovation in cerebrovascular and neurodegenerative disease diagnostics. The tool is enhanced by AI analytics and aims to deliver mass-market screening, even Read more ...
All Deep Tech / Biotech
Project Region: Australia
Fund Stage: Pre-Seed
Problem and Solution:
Problem: Stroke is the 2nd leading cause of global mortality. Current diagnostics are either costly, invasive, or reactive. Alzheimer’s remains undetected until late-stage symptoms appear.
Solution: This platform uses AI to analyze non-invasive enzyme signals from saliva—delivering affordable, scalable screening at the pre-symptomatic stage. It also trains and funds medical innovators to fast-track new neurodiagnostic solutions to market.
Project Region: Australia
Raise Size (Estimated in USD): 500K to 1M
An Australian-based unlisted biotech advancing a dual human-animal pipeline in oncology and wound healing using a proprietary biodiscovery platform. Its lead drug targets solid tumours via direct injection, showing pan-tumour activity in both veterinary and human clinical trials. The second asset is a topical agent for chronic and acute wounds, Read more ...
Project Region: Australia
Fund Stage: Mature / Pre-IPO
Problem and Solution:
Problem: Solid tumours and non-healing wounds continue to represent billion-dollar treatment gaps with limited targeted solutions and long development cycles.
Solution: A patented class of small molecules sourced from natural environments, designed to destroy tumours from within and accelerate wound recovery—already proven in animals and progressing in humans.
Project Region: Australia
Raise Size (Estimated in USD): 500K to 1M

